Three oxygenated analogues of the prenylated phloroglucinol hyperforin (3-5) were isolated from the aerial parts of Hypericum perforatum and their structures elucidated by spectroscopic methods.
Background: Non-alcoholic fatty liver disease is the most common cause of liver-related morbidity and mortality in the world. However, no effective pharmacological treatment for this condition has been found. Purpose: This study evaluated the effect of a nutraceutical containing bioactive components from Bergamot citrus and wild cardoon as a treatment for individuals with fatty liver disease. The primary outcome measure was the change in liver fat content. Methods: A total of 102 patients with liver steatosis were enrolled in a double-blind placebo controlled clinical trial. The intervention group received a nutraceutical containing a Bergamot polyphenol fraction and Cynara Cardunculus extract, 300 mg/day for 12 weeks. The control group received a placebo daily. Liver fat content, by transient elastography, serum transaminases, lipids and glucose were measured at the baseline and the end of the study. Results: We found a greater liver fat content reduction in the participants taking the nutraceutical rather than placebo (−48.2 ± 39 vs. −26.9 ± 43 dB/m, p = 0.02); The percentage CAP score reduction was statistically significant in those with android obesity, overweight/obesity as well as in women. However, after adjustment for weight change, the percentage CAP score reduction was statistically significant only in those over 50 years (44 vs. 78% in placebo and nutraceutical, respectively, p = 0.007). Conclusions: This specific nutraceutical containing bioactive components from Bergamot and wild cardoon reduced the liver fat content during 12 weeks in individuals with liver steatosis over 50 years. If confirmed, this nutraceutical could become the cornerstone treatment of patients affected by liver steatosis. Clinical Trial Registration: www.isrctn.com, identifier ISRCTN12833814.
Objective: Hyperlipemia represents an independent risk factor in the development of atherosclerosis
in patients undergoing type 2 diabetes mellitus (DM). Moreover, the pharmacological treatment
of dyslipemia in patients undergoing type 2 DM (e.g. by means of statins), is accompanied by
relevant side effects and oral supplementation with natural antioxidants, such as Citrus polyphenols,
has recently been suggested to improve cardioprotection in such patients. However, due to the poor
gastrointestinal absorption of polyphenols, novel formulations have recently been developed for getting
a better bioavailability of polyphenolic rich fractions of citrus species extract rich in polyphenols.
Methods:
Here, we investigated the effect of standard bergamot polyphenolic fraction (BPF®) as well
as of its phytosomal formulation (BPF Phyto), in patients with type 2 DM and hyperlipemia. A randomized,
double blind, placebo-controlled study was carried out in 60 patients suffering from type 2
DM and mixed hyperlipemia.
</P><P>
Patients were divided into three groups: one receiving placebo, the second receiving standard BPF and
the third BPF Phyto.
Results:
In the groups receiving BPF and BPF Phyto, a significant reduction of fasting plasma glucose,
serum LDL cholesterol and triglycerides accompanied by increased HDL cholesterol was observed.
This effect was associated with significant reduction of small dense atherogenic LDL particles, as detected
by means of proton NMR Spectroscopy, thus confirming the hypolipemic and hypoglycemic
effect of bergamot extract both when using standard formulation as well as BPF Phyto. No differences
were seen in the therapeutic response among groups receiving BPF and BPF Phyto, thus suggesting a
substantial bioequivalence in their hypoglycemic and hypolipemic profile. However, when comparing
the pharmacokinetic profile of naringin (the major component of BPF) and its metabolites, in patients
treated with BPF Phyto, an at least 2,5 fold increase in its absorption was found, confirming in human
studies the better profile of BPF Phyto compared to standard BPF.
Conclusion:
These data suggest that better absorption and tissue distribution of BPF Phyto formulation
represents an innovative approach in supplementation treatments of cardiometabolic disorders.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.